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Background 
The majority of patients undergoing surgical treatment for 
ST-elevation myocardial infarction receive antifibrinolytic 
therapy to limit blood loss. This approach appears 
counterintuitive to the accepted medical treatment of the 
same condition--namely, fibrinolysis to limit thrombosis. 
Despite this concern, no independent, large-scale safety 
assessment has been undertaken. 
Methods 
Design and setting: Prospective observational cohort 
study in 69 institutions in North and South America, the 
Middle East, Europe, and Asia. 
Subjects:  4374 patients undergoing coronary-artery 
revascularization. All patients were > 18 years old and 
completed a pre-surgery interview. Patients were classified 
as undergoing primary surgery (no previous heart surgery 
and no other surgery besides a coronary artery bypass 
graft), or complex surgery (all other surgery). 
Intervention: None. 
Measurements: The authors prospectively assessed three 
agents (aprotinin [1295 patients], aminocaproic acid [883], 
and tranexamic acid [822]) as compared with no agent 
(1374 patients) with regard to serious cardiovascular, renal, 
and cerebrovascular outcomes by propensity and 
multivariable methods. 
Results:  In propensity-adjusted, multivariable logistic 
regression (C-index, 0.72), use of aprotinin was associated 
with a doubling in the risk of renal failure requiring dialysis 
among patients undergoing complex coronary-artery 
surgery (odds ratio, 2.59; 95 percent confidence interval, 
1.36 to 4.95) or primary surgery (odds ratio, 2.34; 95 
percent confidence interval, 1.27 to 4.31). Similarly, use of 
aprotinin in the latter group was associated with a 55 
percent increase in the risk of myocardial infarction or heart 
failure (P<0.001) and a 181 percent increase in the risk of 
stroke or encephalopathy (P=0.001). Neither aminocaproic 
acid nor tranexamic acid was associated with an increased 
risk of renal, cardiac, or cerebral events. Adjustment 
according to propensity score for the use of any one of the 
three agents as compared with no agent yielded nearly 
identical findings. All the agents reduced blood loss. 
Conclusion 
The association between aprotinin and serious end-organ 
damage indicates that continued use is not prudent. In 
contrast, the less expensive generic medications 
aminocaproic acid and tranexamic acid are safe 
alternatives. 
Commentary 
The medical and surgical approaches to acute ST-elevation 
myocardial infarction present an interesting paradox. The 
medical approach focuses on fibrinolytic therapy. Due to 
concerns over bleeding, the surgical approach avoids 
fibrinolytic agents and instead uses agents that mitigate 
bleeding, so called antifibrinolytic agents, which include 
aprotinin, aminocaproic acid, and tranexamic acid. These 
agents were generally considered safe based on a number 
of secondary analyses of studies that were not primarily 
intended to assess safety. These relatively small studies 
were underpowered to detect adverse events and did not 
involve head-to-head comparisons of the commonly used 
antifibrinolytic agents. Animal studies suggest that these 
agents have the potential to cause ischemic damage to 
multiple organ systems and small, largely single-center 
studies have suggested increased graft thrombosis and 
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renal dysfunction [2-6]. Ideally, the safety of these agents 
would be compared in a large, multi-center, randomized 
controlled trial. However, because their use is embedded in 
practice and because regulatory approval of these agents 
differs by country, conducting such a trial will be difficult if 
not impossible. 
To address the safety of these agents for cardiopulmonary 
bypass surgery, Mangano and colleagues [1] conducted a 
large, prospective, observational cohort assessing aprotinin, 
aminocaproic acid, and tranexamic acid as compared to no 
agent in 4374 patients undergoing revascularization. 
Because this was a prospective study, the authors were 
able to collect a wealth of clinical information, including 
approximately 7500 data fields per patient. This permitted 
consideration of variables that might influence both choice 
of antifibrinolytic agent and clinical outcome. The authors 
used a propensity score based on 45 treatment-selection 
covariates and multivariable modeling to control for baseline 
differences between groups. In doing so, they found that 
aprotinin, but not aminocaproic acid or tranexamic acid, was 
associated with serious cardiovascular, renal, and 
cerebrovascular adverse events. Furthermore, a dose-
response relationship was demonstrated, strengthening the 
inference of causality. 
The main weakness of this study is that the authors failed to 
report details of the surgery itself, such as whether the 
surgery was on vs. off-pump, time on pump, and number of 
vessels bypassed. These variables are likely to influence 
not only choice of antifibrinolytic agent but also outcome, 
and are, therefore, a source of indication bias that could 
reflect unfavorably on aprotinin. 
Based on the results of this study and those of another 
observational study suggesting renal toxicity [7], the United 
States Food and Drug Administration (FDA) held an 
advisory committee meeting September 21, 2006 to 
consider the cardiovascular safety of aprotinin. Because of 
concerns about the methodology of the study by Mangano 
and colleagues and because it was the only study to 
suggest cardiovascular adverse events [8], the advisory 
committee concluded that there was insufficient evidence to 
support changing the cardiovascular safety labeling of the 
drug. However, just six days after the committee met, it was 
revealed that the drug’s manufacturer, Bayer, had 
preliminary results from an observational study of 67,000 
cardiac bypass patients that suggested aprotinin was 
associated with increased risk of death, renal dysfunction, 
congestive heart failure, and stroke [9]. The FDA 
subsequently issued a statement indicating it was unaware 
of this study when the advisory committee met and that it is 
evaluating the results of this study and the potential 
implications for the use of aprotinin [10]. In the mean time, 
the FDA suggests that physicians who use aprotinin should 
carefully monitor patients for the occurrence of toxicity, 
particularly to the kidneys, heart, or brain, and promptly 
report observed adverse events. They go on to recommend 
that physicians should consider limiting aprotinin use to 
those situations where the clinical benefit of reduced blood 
loss is essential to medical management of the patient and 
outweighs the potential risks. 
Recommendation 
The weight of evidence suggests that aprotinin increases 
the risk for a poor outcome among patients undergoing 
cardiac operations. Not only is this drug very expensive, it 
seems to be toxic. Although the risk of excessive bleeding is 
certainly a cause for concern in certain patients, and 
treatment with aprotinin can decrease blood loss in selected 
patients, data are lacking to show that administration of this 
agent actually improves survival. 
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